Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Solid Biosciences Inc. Director's Dealing 2025

Jan 7, 2025

33003_dirs_2025-01-07_2865adfc-886b-4ba8-9b2f-cb6448eeadb8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Solid Biosciences Inc. (SLDB)
CIK: 0001707502
Period of Report: 2025-01-03

Reporting Person: Ganot Ilan (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-01-03 Common Stock M 2994 Acquired 12501 Indirect
2025-01-06 Common Stock S 1056 $4.31 Disposed 11445 Indirect

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-01-03 Restricted Stock Units $ M 2994 Disposed Common Stock (2994) Indirect

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 94807 Direct
Common Stock 19394 Indirect

Footnotes

F1: Restricted stock units convert to common stock on a one-for-one basis.

F2: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The sales do not represent a discretionary trade by Ms. Ganot.

F3: Represents 90,765 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship.

F4: Represents 19,394 shares held by Adam Ganot and Annie Ganot, and their successors, as the trustees for the Ilan Ganot 2017 Irrevocable Trust dated March 3, 2017.

F5: On January 3, 2023 (the "Grant Date"), Ms. Ganot was granted 11,975 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date.